Social Media Ideas for Drug Regulation

Govt Plans Tighter Rules For Prescription Drug Ads, Pharmacies And Wholesalers In Focus

The Union Health Ministry has proposed stricter advertising rules for prescription medicines, extending restrictions beyond drug manufacturers to pharmacies, wholesalers and distri...

Proposed H.R. 10336 Would Balance Innovation, Access to Dietary Supplements—Yet Change the Definition

On September 10, 2026, Congresswoman Diana Harshbarger (R-TN) introduced H.R. 10336—the Dietary Supplement Innovation Act—which would modernize the U.S. Food and Drug Administratio...

Dietary Supplement Innovation Act Aims to Address Drug Preclusion Concerns

Representative Diana Harshbarger (R-TN) recently introduced the Dietary Supplement Innovation Act (H.R. 10336), legislation that would amend the Federal Food, Drug, and Cosmetic Ac...

Centre sets up panel to review pharma marketing rules, examine need for stronger legal framework

The committee has specifically been asked to examine and recommend appropriate regulatory, statutory or other legal measures

The Way the FDA and DEA Ban Drugs Is Unaccountable and Arbitrary

A new report from the Government Accountability Office reveals that federal drug regulators do not have any clear policies or procedures for making scheduling decisions.

Regulating a Moving Target – FDA Seeks Comments on Possible Framework for Regulation of GenAI

By Adrienne R. Lenz, Principal Medical Device Regulation Expert —

SEC and FDA Partner on Legal Compliance for Food and Drug Industries

From State Regulation to Federal Rescheduling: Lessons Learned and the Road Ahead

Much of the discussion surrounding federal cannabis rescheduling has focused on what the industry stands to gain from Schedule III treatment. For operators, investors, and regulato...

From Bathroom Shelf to FDA Oversight: What MoCRA Means for Cosmetics Companies

South Africa: Black Market Weight-Loss Drug Sellers Are Moving Fast. South Africa's Regulators Are Struggling To Keep Up

[Bhekisisa] South African regulators have won an important court battle against a pharmacy making its own versions of popular weight-loss injections. But illegal and experimental d...

<![CDATA[How Recent FDA Actions Impact Sponsors]]>

Marijuana Rescheduling Temporarily Paused

On September 29, 2026, U.S. Drug Enforcement Administration’s (DEA) chief administrative law judge (ALJ) paused marijuana rescheduling proceedings to consider a new report on drug...

<![CDATA[What Moments in FDA’s Review Process Should Patients and Providers be Watching Closely?]]>

Can a New Weight Loss Treatment Escape the Legal and Regulatory Thicket?

It’s Eli Lilly vs. RFK Jr. in a battle over the rules around retatrutide.

FDA Medical Devices: Important Regulatory Considerations for Companies Seeking to Enter the U.S. Market

The medical device market in the U.S. is very large and attractive to many companies who are located outside of the U.S. Entering the U.S. medical device market requires a comprehe...

<![CDATA[As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward]]>

Semaglutide-makers to get uniform quality standards as IPC prepares monograph

At present, Indian firms follow their own inhouse standard to manufacture the weight-loss drug

Montana’s Human Experiment with Untested Drugs

Montana has opened a channel for drugs to be sold without the normal requirements of testing for effectiveness and side effects.

A Prescription for Liability- Injunction in Gray-Market Drug Case Based on Material Differences

The FDA Promises To Streamline the Dauntingly Complex Rules for Approving Nicotine Products

The planned reforms could promote harm reduction by addressing a huge backlog that has resulted in routine violations of a statutory deadline.

GLP-1 Telehealth Ads: What Regulators Flagged in 2026

GLP-1 telehealth ads regulators flagged: generic, same active ingredient and clinically proven claims for compounded drugs, plus a compliance table.

The paperwork problem: How many FDA warning letters actually cite document failures

When people take a medication, they trust that it contains the right amount of active ingredient and is free of harmful contamination. Manufacturing and test records help verify th...

FDA Quietly Included Provision in GRAS Proposed Rule to Expand One ‘Loophole’ While Tightening Another

The proposal would expand the Threshold of Regulation (TOR) exemption to include food additives and ingredients, which would allow chemicals to enter the U.S. food supply without o...

<![CDATA[Life Sciences Compliance: Diagnosis Incomplete]]>